RPTX RSI Chart
Last 7 days
1.7%
Last 30 days
10.9%
Last 90 days
-46.3%
Trailing 12 Months
-61.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 97.9M | 0 | 0 | 0 |
2023 | 111.7M | 91.5M | 71.3M | 51.1M |
2022 | 7.8M | 49.2M | 90.5M | 131.8M |
2021 | 2.0M | 3.9M | 5.7M | 7.6M |
2020 | 0 | 0 | 0 | 135.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 01, 2024 | zinda michael | sold | -1,910 | 4.66 | -410 | evp, chief scientific officer |
Apr 01, 2024 | forte steve | sold | -3,637 | 4.61 | -789 | evp, chief financial officer |
Apr 01, 2024 | segal lloyd mitchell | sold | -11,533 | 4.63 | -2,491 | president and ceo |
Apr 01, 2024 | koehler maria | sold | -1,398 | 4.66 | -300 | evp, chief medical officer |
Mar 28, 2024 | forte steve | sold | -3,811 | 4.62 | -825 | evp, chief financial officer |
Mar 28, 2024 | zinda michael | sold | -2,088 | 4.64 | -450 | evp, chief scientific officer |
Mar 28, 2024 | segal lloyd mitchell | sold | -12,243 | 4.62 | -2,650 | president and ceo |
Mar 28, 2024 | koehler maria | sold | -2,320 | 4.64 | -500 | evp, chief medical officer |
Mar 27, 2024 | zinda michael | sold | -2,079 | 4.62 | -450 | evp, chief scientific officer |
Mar 27, 2024 | forte steve | sold | -3,811 | 4.62 | -825 | evp, chief financial officer |
Which funds bought or sold RPTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Artal Group S.A. | unchanged | - | -1,813,000 | 3,297,000 | 0.08% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -40.45 | -127,817 | 79,759 | -% |
May 15, 2024 | PDT Partners, LLC | new | - | 141,677 | 141,677 | 0.01% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 1,888 | 17,267 | 18,727 | -% |
May 15, 2024 | Aquilo Capital Management, LLC | unchanged | - | -1,640,170 | 2,982,710 | 2.24% |
May 15, 2024 | Deep Track Capital, LP | reduced | -10.3 | -9,203,680 | 12,643,300 | 0.36% |
May 15, 2024 | Blue Owl Capital Holdings LP | unchanged | - | -8,087,270 | 14,707,000 | 2.94% |
May 15, 2024 | Corton Capital Inc. | added | 66.03 | 14,478 | 217,710 | 0.08% |
May 15, 2024 | Oracle Alpha Inc. | added | 58.54 | 2,058 | 91,760 | 0.16% |
May 15, 2024 | Opaleye Management Inc. | new | - | 318,212 | 318,212 | 0.07% |
Unveiling Repare Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Repare Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Repare Therapeutics Inc News
Income Statement (Quarterly) | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Revenue | 301.7% | 52,404,000 | 13,047,000 | 2,159,000 | 30,249,000 | 24,223,500 | 18,198,000 | 112,545,000 | 56,476,500 | 408,000 | 6,877,000 | 278,000 | 279,000 | 166,000 | - |
Operating Expenses | -5.3% | 41,588,000 | 43,914,000 | 40,577,000 | 42,507,000 | 40,359,000 | 37,830,000 | 39,146,000 | 39,413,000 | 35,237,000 | 35,611,000 | 31,957,000 | 26,946,000 | 21,746,000 | 17,212,000 |
S&GA Expenses | -100.0% | - | 8,648,000 | 7,868,000 | 8,719,000 | 8,529,000 | 7,939,000 | 7,904,000 | 7,938,000 | 8,779,000 | 7,639,000 | 6,596,000 | 6,741,000 | 5,237,000 | 4,795,000 |
R&D Expenses | -6.5% | 32,970,000 | 35,266,000 | 32,709,000 | 33,788,000 | 31,830,000 | 29,891,000 | 31,242,000 | 31,475,000 | 26,458,000 | 27,972,000 | 25,361,000 | 20,205,000 | 16,509,000 | 12,417,000 |
EBITDA Margin | 71.8% | -0.54 | -1.92 | -1.24 | 0.25 | -0.06 | -0.08 | -0.26 | -2.67 | -15.28 | -14.06 | -16.59 | -19.99 | - | - |
Income Taxes | 231.1% | 629,000 | 190,000 | -16,299,000 | 3,110,000 | 3,616,000 | 15,028,000 | 54,000 | 33,000 | 32,000 | -412,000 | -708,000 | -421,000 | -137,000 | -1,554,000 |
Earnings Before Taxes | 149.5% | 13,791,000 | -27,840,000 | -35,178,000 | -8,836,000 | -31,325,000 | -16,630,000 | 75,515,000 | -38,060,000 | -34,725,000 | -28,702,000 | -31,600,000 | -26,730,000 | -21,554,000 | -16,817,000 |
EBT Margin | 70.6% | -0.59 | -2.02 | -1.29 | 0.20 | -0.09 | -0.11 | -0.29 | -2.71 | -15.53 | -14.29 | -16.87 | -20.36 | - | - |
Net Income | 147.0% | 13,162,000 | -28,030,000 | -18,879,000 | -11,946,000 | -34,941,000 | -31,658,000 | 75,461,000 | -38,093,000 | -34,757,000 | -28,290,000 | -30,892,000 | -26,309,000 | -21,417,000 | -15,263,000 |
Net Income Margin | 74.5% | -0.47 | -1.83 | -1.37 | -0.03 | -0.26 | -0.22 | -0.28 | -2.69 | -15.33 | -14.07 | -16.37 | -19.84 | - | - |
Free Cashflow | 141.8% | 11,932,000 | -28,554,000 | -32,870,000 | -35,411,000 | -32,261,000 | -27,917,000 | 87,892,000 | -29,762,000 | -30,493,000 | -20,903,000 | -33,097,000 | -18,487,000 | - | - |
Balance Sheet | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
Assets | 3.6% | 263 | 254 | 286 | 302 | 336 | 364 | 409 | 308 | 337 | 369 | 296 | 321 | 339 | 357 | 370 | 382 | 103 |
Current Assets | 4.5% | 255 | 244 | 275 | 292 | 326 | 354 | 391 | 290 | 319 | 351 | 280 | 309 | 328 | 347 | 361 | 377 | 99.00 |
Cash Equivalents | -7.2% | 103 | 111 | 107 | 116 | 121 | 160 | 155 | 276 | 305 | 334 | 261 | 294 | 312 | 326 | 348 | 370 | 95.00 |
Net PPE | -11.9% | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 2.00 | 2.00 |
Liabilities | -25.6% | 31.00 | 42.00 | 53.00 | 56.00 | 85.00 | 85.00 | 103 | 83.00 | 78.00 | 80.00 | 77.00 | 76.00 | 71.00 | 70.00 | 69.00 | 68.00 | 13.00 |
Current Liabilities | -21.8% | 31.00 | 39.00 | 49.00 | 53.00 | 81.00 | 79.00 | 62.00 | 39.00 | 34.00 | 35.00 | 23.00 | 23.00 | 12.00 | 11.00 | 10.00 | 10.00 | 4.00 |
Shareholder's Equity | 9.4% | 232 | 212 | 233 | 245 | 251 | 280 | 306 | 226 | 259 | 288 | 218 | 245 | 268 | 287 | 301 | 314 | - |
Retained Earnings | 3.9% | -319 | -333 | -305 | -286 | -274 | -239 | -207 | -283 | -245 | -210 | -181 | -151 | -124 | -103 | -88.09 | -74.34 | -49.94 |
Additional Paid-In Capital | 6.2% | 66.00 | 62.00 | 56.00 | 49.00 | 43.00 | 37.00 | 32.00 | 27.00 | 23.00 | 18.00 | 14.00 | 11.00 | 8.00 | 6.00 | 5.00 | 4.00 | 4.00 |
Shares Outstanding | 0.6% | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 37.00 | 37.00 | - | - | - | - | - |
Float | - | - | - | - | 383 | - | - | - | 455 | - | - | - | 812 | - | - | - | 704 | - |
Cashflow (Quarterly) | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 |
Cashflow From Operations | 142.4% | 11,932 | -28,156 | -32,870 | -34,346 | -31,786 | -29,637 | 88,158 | -28,193 | -30,006 | -20,738 | -32,773 | -18,058 | -14,227 | -12,947 | -20,104 | 36,684 | -9,717 | - | - | - |
Share Based Compensation | 1.8% | 6,475 | 6,359 | 6,377 | 6,265 | 6,062 | 5,138 | 5,053 | 4,745 | 4,755 | 3,896 | 3,693 | 3,183 | 2,057 | 1,006 | 871 | 389 | 271 | - | - | - |
Cashflow From Investing | -163.7% | -20,316 | 31,879 | 24,498 | 28,350 | -6,686 | 34,058 | -208,930 | -1,309 | 403 | -398 | -389 | -117 | -772 | -9,247 | -473 | -13.00 | -30.00 | - | - | - |
Cashflow From Financing | 257.1% | 375 | 105 | 284 | 40.00 | 413 | 165 | 269 | 205 | 241 | 94,562 | 363 | 449 | 183 | 289 | -1,695 | 249,026 | 222 | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue: | ||
Collaboration agreements | $ 52,404 | $ 5,678 |
Operating expenses: | ||
Research and development, net of tax credits | 32,970 | 31,830 |
General and administrative | 8,618 | 8,529 |
Total operating expenses | 41,588 | 40,359 |
Income (loss) from operations | 10,816 | (34,681) |
Other income (expense), net | ||
Realized and unrealized gain (loss) on foreign exchange | 31 | (56) |
Interest income | 2,968 | 3,427 |
Other expense | (24) | (15) |
Total other income, net | 2,975 | 3,356 |
Income (loss) before income taxes | 13,791 | (31,325) |
Income tax expense | (629) | (3,616) |
Net income (loss) | 13,162 | (34,941) |
Unrealized (loss) gain on available-for-sale marketable securities | (141) | 193 |
Total other comprehensive (loss) income | (141) | 193 |
Comprehensive income (loss) | $ 13,021 | $ (34,748) |
Net income (loss) per share attributable to common shareholders--basic | $ 0.31 | $ (0.83) |
Net income (loss) per share attributable to common shareholders--diluted | $ 0.3 | $ (0.83) |
Weighted-average common shares outstanding-basic | 42,234,001 | 42,040,674 |
Weighted-average common shares outstanding-diluted | 44,024,198 | 42,040,674 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 103,217 | $ 111,268 |
Marketable securities | 133,784 | 112,359 |
Income tax receivable | 10,829 | 10,813 |
Other current receivables | 3,377 | 4,499 |
Prepaid expenses | 3,463 | 4,749 |
Total current assets | 254,670 | 243,688 |
Property and equipment, net | 3,714 | 4,215 |
Operating lease right-of-use assets | 2,763 | 3,326 |
Income tax receivable | 1,630 | 2,276 |
Other assets | 307 | 396 |
TOTAL ASSETS | 263,084 | 253,901 |
CURRENT LIABILITIES: | ||
Accounts payable | 6,825 | 2,400 |
Accrued expenses and other current liabilities | 20,454 | 24,057 |
Operating lease liability, current portion | 2,218 | 2,400 |
Deferred revenue, current portion | 1,073 | 10,222 |
Total current liabilities | 30,570 | 39,079 |
Operating lease liability, net of current portion | 561 | 1,010 |
Deferred revenue, net of current portion | 0 | 1,730 |
TOTAL LIABILITIES | 31,131 | 41,819 |
SHAREHOLDERS’ EQUITY | ||
Preferred shares, no par value per share; unlimited shares authorized as of March 31, 2024 and December 31, 2023, respectively; 0 shares issued and outstanding as of March 31, 2024, and December 2023, respectively | 0 | 0 |
Common shares, no par value per share; unlimited shares authorized as of March 31, 2024 and December 31, 2023; 42,445,406 and 42,176,041 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 486,375 | 483,350 |
Additional paid-in capital | 65,638 | 61,813 |
Accumulated other comprehensive (loss) income | (113) | 28 |
Accumulated deficit | (319,947) | (333,109) |
Total shareholders’ equity | 231,953 | 212,082 |
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ 263,084 | $ 253,901 |